JH87
2021-07-29
To the moon!!
Tilray CEO Irwin Simon Discusses Earnings Report And Surge In Stock On Benzinga Cannabis Hour
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":801531727,"tweetId":"801531727","gmtCreate":1627522181369,"gmtModify":1633764172245,"author":{"id":3586731369549561,"idStr":"3586731369549561","authorId":3586731369549561,"authorIdStr":"3586731369549561","name":"JH87","avatar":"https://static.tigerbbs.com/51814e4251837f4c5551dfa87f49be4d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>To the moon!!</p></body></html>","htmlText":"<html><head></head><body><p>To the moon!!</p></body></html>","text":"To the moon!!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/801531727","repostId":2155973148,"repostType":4,"repost":{"id":"2155973148","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627521485,"share":"https://www.laohu8.com/m/news/2155973148?lang=&edition=full","pubTime":"2021-07-29 09:18","market":"us","language":"en","title":"Tilray CEO Irwin Simon Discusses Earnings Report And Surge In Stock On Benzinga Cannabis Hour","url":"https://stock-news.laohu8.com/highlight/detail?id=2155973148","media":"Benzinga","summary":"Tilray Inc (NASDAQ: TLRY) CEO Irwin Simon spoke with Javier Hasse and Patrick Lane on Wednesday’s Cannabis Hour following the release of the company’s May quarter earni","content":"<p><b>Tilray Inc </b>(NASDAQ:TLRY) CEO Irwin Simon spoke with <b>Javier Hasse and Patrick Lane</b> on Wednesday’s<b> Cannabis Hour</b> following the release of the company’s May quarter earnings report, after which Tilray’s shares were up roughly 25%.</p>\n<p>Simon began the interview by noting that 2020 was a year to remember for various reasons, including COVID and his own company’s rise to the top of the cannabis food chain.</p>\n<p><b>How and why has Tilray’s growth been so outstanding?</b></p>\n<p>It’s not the first time Simon has said this but it bears repeating:<b> cannabis is here to stay.</b></p>\n<p>“The demand for cannabis and the companies who build brands continue to grow, ” Simon said.</p>\n<p>Asked about the company’s internal and very ambitious plan that involves the no small goal of becoming a <b>$4 billion company in the coming two years</b>, Simon laid out his plans and how Tilray intends to carry them out.</p>\n<p><b>The first on the list was basic</b>: get bigger, which would entail acquisitions. Which U.S. MSOs might Tilray might be looking to acquire? No details on that score but he said which states they’ll be looking at: the biggest ones – California, New York and Florida for starters, Simon told Hasse and Elliot.</p>\n<p>2. <b>Products and more products</b>: Tilray is already on the beer and beverage train but Simon likes the idea of consumption goods, mostly in the edibles, drinks and snack area.</p>\n<p>3. <b>Geographical growth</b>: Simon mentioned gaining sales in U.S. states and Canada. Then there’s Europe where Tilray already dominates the largest market, Germany, and is looking at Portugal and Poland with Israel being an important market as well. In terms of distribution in Europe, Tilray already has CC Pharma in place and sees legal adult-use markets growing across Europe in the near future.</p>\n<p><b>In terms of growth, “Our edge is our experience” Simon added.</b></p>\n<p>While all of the above is happening, Tilray will “ensure low-cost production and good value for consumers,” Simon noted.</p>\n<p>While Simon is clearly optimistic that legalization in the U.S. is in the cards, and soon, he called his $4 billion goal “aspirational.”</p>\n<p>“My aspirations are built on legalization in the United States.”</p>\n<p>Asked what it felt like to be on top, Simon’s confidence was mixed with a dose of caution.</p>\n<p>“Nimble, flexible, entrepreneurial…but you have to be aware of who will soon be nibbling at your heels.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray CEO Irwin Simon Discusses Earnings Report And Surge In Stock On Benzinga Cannabis Hour</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray CEO Irwin Simon Discusses Earnings Report And Surge In Stock On Benzinga Cannabis Hour\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-29 09:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tilray Inc </b>(NASDAQ:TLRY) CEO Irwin Simon spoke with <b>Javier Hasse and Patrick Lane</b> on Wednesday’s<b> Cannabis Hour</b> following the release of the company’s May quarter earnings report, after which Tilray’s shares were up roughly 25%.</p>\n<p>Simon began the interview by noting that 2020 was a year to remember for various reasons, including COVID and his own company’s rise to the top of the cannabis food chain.</p>\n<p><b>How and why has Tilray’s growth been so outstanding?</b></p>\n<p>It’s not the first time Simon has said this but it bears repeating:<b> cannabis is here to stay.</b></p>\n<p>“The demand for cannabis and the companies who build brands continue to grow, ” Simon said.</p>\n<p>Asked about the company’s internal and very ambitious plan that involves the no small goal of becoming a <b>$4 billion company in the coming two years</b>, Simon laid out his plans and how Tilray intends to carry them out.</p>\n<p><b>The first on the list was basic</b>: get bigger, which would entail acquisitions. Which U.S. MSOs might Tilray might be looking to acquire? No details on that score but he said which states they’ll be looking at: the biggest ones – California, New York and Florida for starters, Simon told Hasse and Elliot.</p>\n<p>2. <b>Products and more products</b>: Tilray is already on the beer and beverage train but Simon likes the idea of consumption goods, mostly in the edibles, drinks and snack area.</p>\n<p>3. <b>Geographical growth</b>: Simon mentioned gaining sales in U.S. states and Canada. Then there’s Europe where Tilray already dominates the largest market, Germany, and is looking at Portugal and Poland with Israel being an important market as well. In terms of distribution in Europe, Tilray already has CC Pharma in place and sees legal adult-use markets growing across Europe in the near future.</p>\n<p><b>In terms of growth, “Our edge is our experience” Simon added.</b></p>\n<p>While all of the above is happening, Tilray will “ensure low-cost production and good value for consumers,” Simon noted.</p>\n<p>While Simon is clearly optimistic that legalization in the U.S. is in the cards, and soon, he called his $4 billion goal “aspirational.”</p>\n<p>“My aspirations are built on legalization in the United States.”</p>\n<p>Asked what it felt like to be on top, Simon’s confidence was mixed with a dose of caution.</p>\n<p>“Nimble, flexible, entrepreneurial…but you have to be aware of who will soon be nibbling at your heels.”</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155973148","content_text":"Tilray Inc (NASDAQ:TLRY) CEO Irwin Simon spoke with Javier Hasse and Patrick Lane on Wednesday’s Cannabis Hour following the release of the company’s May quarter earnings report, after which Tilray’s shares were up roughly 25%.\nSimon began the interview by noting that 2020 was a year to remember for various reasons, including COVID and his own company’s rise to the top of the cannabis food chain.\nHow and why has Tilray’s growth been so outstanding?\nIt’s not the first time Simon has said this but it bears repeating: cannabis is here to stay.\n“The demand for cannabis and the companies who build brands continue to grow, ” Simon said.\nAsked about the company’s internal and very ambitious plan that involves the no small goal of becoming a $4 billion company in the coming two years, Simon laid out his plans and how Tilray intends to carry them out.\nThe first on the list was basic: get bigger, which would entail acquisitions. Which U.S. MSOs might Tilray might be looking to acquire? No details on that score but he said which states they’ll be looking at: the biggest ones – California, New York and Florida for starters, Simon told Hasse and Elliot.\n2. Products and more products: Tilray is already on the beer and beverage train but Simon likes the idea of consumption goods, mostly in the edibles, drinks and snack area.\n3. Geographical growth: Simon mentioned gaining sales in U.S. states and Canada. Then there’s Europe where Tilray already dominates the largest market, Germany, and is looking at Portugal and Poland with Israel being an important market as well. In terms of distribution in Europe, Tilray already has CC Pharma in place and sees legal adult-use markets growing across Europe in the near future.\nIn terms of growth, “Our edge is our experience” Simon added.\nWhile all of the above is happening, Tilray will “ensure low-cost production and good value for consumers,” Simon noted.\nWhile Simon is clearly optimistic that legalization in the U.S. is in the cards, and soon, he called his $4 billion goal “aspirational.”\n“My aspirations are built on legalization in the United States.”\nAsked what it felt like to be on top, Simon’s confidence was mixed with a dose of caution.\n“Nimble, flexible, entrepreneurial…but you have to be aware of who will soon be nibbling at your heels.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":157,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/801531727"}
精彩评论